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Abstract 
Objective: Thyroid cancer incidence has increased substantially in the United States. Previous 
studies of the relationship between cigarette smoking and thyroid cancer have yielded conflicting 
results. 
Methods: In order further clarify the association between cigarette smoking and risk of thyroid 
cancer, we analyzed data from a population-based case-control study in Connecticut in 2010-
2011 including 462 histologically confirmed incident thyroid cancer cases and 498 population-
based controls. Multivariate unconditional logistic regression models were used to estimate the 
associations between cigarette smoking and risk of thyroid cancer adjusting for potential 
confounders. 
Results: Our data showed a decreased risk of well-differentiated thyroid carcinoma among 
microcarcinomas (tumor size less than or equal to 1cm) by current smoker (OR=0.30, 95%CI 
0.13, 0.70), lowest intensity category (OR=0.33, 95%CI 0.15- 0.74) as well as longest duration 
category (OR=0.18, 95%CI 0.07-0.47). No significant associations were found between these 
smoking predictors and macrocarcinomas (tumor size larger than 1cm).  
Conclusions: Our study findings are consistent with a number of several previous epidemiologic 
studies indicating that cigarette smoking is associated with a decreased risk of thyroid cancer. 
The research highlights the significance of distinguishing between microcarcinomas and 
macrocarcinomas in future research on etiology of thyroid cancer. 
Key Words: thyroid cancer, cigarette smoking, case-control study, tumor size  
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1. Introduction 
Over the last few decades, the age-adjusted incidence rate of thyroid cancer has been rapidly 
increasing worldwide1. Compared to all other cancers, the incidence rate increased fastest from 
8.74/100,000 in women and 3.38/100,000 in men in 1994 to 21.82/100,000 in women and 
7.37/100,000 in men in 20112. It is now the fifth most common cancer among women in the 
US2.While the improvement in diagnostic technology such as fine needle aspiration with 
ultrasound guidance may be associated with increased detection of microcarcinomas (diameter<1 
cm), the incidence for both smaller size tumors and larger size tumors were increasing1.Besides, 
studies have shown that approximately fifty percent of the variability in thyroid cancer incidence 
rates in the US, cannot be explained by the “over-diagnosis”3, 4. Therefore, environmental factors 
may also play a role in the thyroid cancer development. There are some well-established risk 
factors for thyroid cancer, including radiation exposure5-7, prior benign thyroid disease7, and 
obesity8. Other risk factors for thyroid cancer are still unclear.  
Cigarette smoking is at least related to 12 cancers according to The International Agency for 
Research on Cancer (IARC) and US Surgeon General (US-SG)9, 10. Previous studies showed 
controversial results about the effect of cigarette smoking on thyroid cancer risk6, 7, 11-23. Several 
of them found statistically significant negative associations between smoking and thyroid cancer 
risk6, 11, 13, 15, 16, 18, 20, 21, while others found no association12, 14, 19, 22-24 or positive association17. 
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In light of the increasing trends of thyroid cancer incidence, especially microcarcinomas, and the 
inconsistent previous study results, we aimed to further clarify the association between cigarette 
smoking and thyroid cancer risk by histological type and tumor size and to get a better 
understanding of the role of cigarette smoking in the risk of thyroid cancer. 
 
2. Literature review 
The effects of smoking on the risk of thyroid cancer were controversial in previous literatures, 
although smoking is a well-established risk factor for many cancers. 
 
There were totally fifteen previous studies investigated the association between smoking 
exposure and risk of thyroid cancer6, 7, 11-23. Six of them found no association between smoking 
exposure and thyroid cancer risk12, 14, 19, 22-24 while eight of them found statistically significant 
negative associations between smoking and thyroid cancer risk6, 11, 13, 15, 16, 18, 20, 21. Only one of 
them found significant positive association17. 
 
All the smoking exposure measurement in previous studies was self-reported. Majority of the 
studies examined the association among female populations6, 7, 12, 13, 15, 16, 18, 21. Only one study 
focused on the association among males only11. The remaining of the studies assessed the 
association between smoking and thyroid caner risk among all participants, regardless of 
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gender14, 17, 19, 20, 22, 23. 
 
There were 4 cohort studies evaluated the association between smoking and thyroid cancer risk20-
23. Among them, one of the used retrospective cohort23 while the other three used prospective 
cohort20-22. Among the remaining 11 out of 15 studies, case-control design was adopted6, 7, 11-19. 
 
With regard to the exposure assessment, all of the studies assessed smoking status, i.e. never or 
ever smoking, former or current smoking. Two of them examined smoking status, age at 
initiation, duration, intensity, pack-years and years since quitting15, 16. Other studies did not 
assess all of these smoking predictors. Among them, five out fifteen only measured smoking 
status without other smoking predictor measurement17-19, 23. 
 
3. Materials and Methods 
3.1 Study population 
The study population has been described elsewhere25. In brief, cases were histologically 
confirmed, incident thyroid cancer patients (ICD-O-3: 8021, 8050, 8052, 8130, 8260, 
8290, 8330-8332, 8335, 8340-8346, 8450, 8452, 8510) in Connecticut diagnosed between 2010 
and 2011. Eligible subjects were aged 21 to 84 years at diagnosis, having no previous diagnosis 
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of cancer, with the exception of non-melanoma skin cancer, and were alive at the time of 
interview. Cases were identified through the Yale Cancer Center’s Rapid Case Ascertainment 
Shared Resource (RCA). RCA acts as an agent of the Connecticut Tumor Registry. The 
Connecticut Public Health Code requires reporting of cancers from licensed hospitals and 
clinical laboratories to the Connecticut Tumor Registry. In order to identify newly diagnosed 
cases, RCA field staffs are assigned geographically to survey all of the state's non-pediatric 
hospitals. Information on cases identified in the field is sent regularly to the RCA data entry staff 
where the case's demographic data are entered, verified and screened against the Connecticut 
Tumor Registry database. The Connecticut Tumor Registry has reciprocal reporting agreements 
with cancer registries in all adjacent states (and Florida) to identify Connecticut residents with 
cancer diagnosed and/or treated in these states. A total of 701 eligible 
incident thyroid cancer cases were identified during the study period with 462 (65.9%) 
completing in-person interviews. Population-based controls with Connecticut addresses were 
recruited using a random digit dialing method. A total of 498 subjects participated in the study, 
with a participation rate of 61.5%. 
years). Distributions of age, gender and race were similar between the participants and non-
participants for both cases and controls.     
 
All procedures were performed in accordance with a protocol approved by the Human 
Investigations Committee at Yale and the Connecticut Department of Public Health. After 
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approval by the hospitals and by each subject’s physician (cancer cases), or following selection 
through random digit dialing sampling (control population), potential participants were 
approached by letter and then by phone. Those who agreed were interviewed by trained study 
interviewers, either at the subject’s home or at a convenient location. After obtaining written 
consent, a standardized, structured questionnaire was used to obtain information on 
sociodemographic characteristics, gynecological and reproductive history, medical history, 
family history, habitual diet, clinical information as well as smoking history. 
 
3.2 Exposure assessment 
Ever smokers were defined as those who smoked at least 100 cigarettes prior to 1 year before the 
disease diagnosis for cases or the interview for controls. Never smokers were those who reported 
smoking less than a total of 100 cigarettes in their lifetime. Ever smokers were further questioned 
as to the age when first started smoking cigarettes, whether or not they were smoking at 
diagnosis (yes/no), age at quitting (former smokers), number of years quitting between first and 
last smoked, and number of cigarettes smoked per day.  
 
3.3 Statistical analysis 
Unconditional logistic regression models were used to estimate the odds ratio (ORs) and 95% 
confidence intervals (95%CI).  By using never smokers as the reference group, ORs and 95% CI 
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were estimated for ever smokers, current smokers, former smokers, age at initiation of smoking 
(<20 and ≥20 years old), intensity of smoking (<10, 10- 20, and ≥20 cigarettes per day), duration 
of smoking (<10, 10- 29, and ≥29 years), pack-years (pack-years= number of packs smoked per 
day times number of years smoked) of exposure (<5, 5 - 24 and ≥24 pack-years), and years since 
quitting smoking (<13, 13- 28 and ≥28 years).All cut points were based on the distribution 
among control subjects. We also restricted our analyses to papillary and well-differentiated 
(papillary and follicular combined due to the small sample size of follicular carcinoma) thyroid 
cancer subtypes. In order to exam the effect of smoking status on tumor size, analyses were also 
conducted by dividing the cases into two groups according to the tumor size (≤ 1cm, >1 cm) 
among papillary and well-differentiated carcinoma, respectively. We also analyzed thyroid 
cancer among women because the number of men was too small for a meaningful analysis.  
 
462 cases and 498 controls were included in the final analysis with known smoking status. Age, 
gender, race, family history of any cancer, education, BMI, previous benign thyroid diseases, 
history of radiation exposure and previous alcohol consumption were considered as potential 
confounding variables and were controlled in the model. Decisions on which covariates to 
include in the final model were based on a greater than 10% change in the estimates. Tests for 
linear trends were calculated by using smoking predictor variables as continuous variables in the 
multivariate unconditional logistic regression models. 
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Statistical analyses for this study were performed by using the SAS system version 9.3 (SAS 
Institute Inc., Cary, NC, USA). Results were considered statistical significance when 2-sided p-
values were <0.05. 
 
4. Results 
4.1 Description of study population 
The majority of 462 cases were diagnosed with papillary thyroid cancer (392, 84.8%) followed 
by follicular (56, 12.1%), medullary (12, 2.6%), anaplastic (1, 0.2%), and others (1, 0.2%). A 
total of 217 (47.0%) cases were microcarcinomas, and among them, 190 were papillary and 24 
were follicular. 
 
As illustrated in Table 1, the selected demographic characteristics of cases and controls were 
compared. Interviewed cases and controls were similar with respect to race and family history of 
any cancer, as well as previous radiation exposure. Compared to controls, cases tended to be less 
highly educated and have a higher BMI (p<0.01). Cases were more likely to have prior benign 
thyroid disease (p<0.01). Besides, 40.7% of cases had ever used alcohol compared to 53.6% of 
alcohol usage among controls (p<0.01). Cases were also more likely to be female compared to 
controls (p=0.0003). 
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4.2 Primary analysis 
Table 2 showed the risk of thyroid cancer associated with smoking for all thyroid cancer 
subtypes combined. When compared to those who have never smoked, the risk of thyroid cancer 
did not seem to be changed significantly by ever, current, former smoking status, or pack-years. 
And the results did not show a trend of increasing risk associated with increasing years since 
stopping smoking or the age started smoking. Reduced risk was seen in the low intensity 
category with less than 10 cigarettes per day (OR=0.52, 95%CI 0.30-0.90) and longest duration 
category (OR=0.42, 95%CI 0.23-0.81). And there is a statistical significant negative trend of 
duration (P for trend linear=0.01). 
 
4.3 Stratified analysis 
When we restricted the analysis to different histological subtypes, there was a reduction in the 
risk of well-differentiated thyroid cancer with regard to current smoker (OR=0.51, 95%CI 0.28- 
0.94) and lowest intensity category (OR=0.53, 95%CI 0.31-0.93)(Table 3). Moreover, smokers 
who smoked 29 years or more experience a 60% reduced risk (OR=0.40, 95%CI 0.21- 0.76) of 
developing well-differentiated carcinoma compared with never smokers, illustrating a dose-
response relationship between smoking duration and well-differentiated carcinoma (P for linear 
trend=0.01). There was a negative association between papillary carcinoma and smoking 
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duration more than 29 years (OR=0.38, 95%CI 0.19-0.77) as well as a significant linear trend (p 
for linear trend=0.01). No significant associations were observed for ever or former smokers, age 
at initiation, pack-years, or years since quitting with the risk of well-differentiated and papillary 
thyroid carcinoma. 
 
The risk of thyroid cancer associated with cigarette smoking by tumor size was presented in 
Table 4. A reduction in the risk of well-differentiated thyroid microcarcinomas were observed 
for current smokers (OR=0.30, 95%CI 0.13- 0.70), lowest intensity category (OR=0.33, 95%CI 
0.15- 0.74), as well as the longest duration category (OR=0.18, 95%CI 0.07-0.47). A dose-
response relationship between duration of smoking and well-differentiated thyroid 
microcarcinomas (P for linear trend<0.01) was also observed. Similar patterns were also seen in 
papillary thyroid microcarcinomas. No significant associations with smoking were shown for 
either well-differentiated or papillary thyroid carcinoma with tumor size larger than 1cm.  
 
We also analyzed the risk of thyroid cancer by smoking among women (Table 6). Similar 
associations were found among women which suggests that gender was not an effect modifier. 
Table 7 showed the association between thyroid cancer risk and cigarette smoking among men 
where no significant results were observed. 
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Risk of thyroid cancer associated with cigarette smoking by tumor size among all cancer types is 
showed in Table 8. No significant result was observed among macrocarcinomas. 
 
4.4 Sensitivity analysis 
Sensitivity analyses showed that the association between smoking predictors and risk of well-
differentiated microcarcinomas (Table 6) and papillary microcarcinomas (Table 7) did not 
materially changed, implying the robust association between smoking and thyroid cancer. 
 
5. Discussion 
In this population-based case-control study, ever smokers did not seem to change the risk of 
thyroid cancer overall. Being a current smoker, smoking less than 10 cigarettes per day, and 
increasing duration of smoking appeared to be associated with a reduced risk of thyroid cancer 
overall. Besides, smoking duration showed a significant inverse linear dose-response in risk of 
thyroid cancer. Restriction to females alone demonstrated similar results pattern with regard to 
thyroid cancer risk by current smokers, lowest smoking intensity category as well as longest 
smoking duration category. Similar results, except for significant negative linear trends in 
duration, were only shown in well-differentiated carcinoma, although it is not surprising due to 
the smaller sample size of papillary carcinoma subtypes if the association is weak. When further 
stratified by tumor size among well-differentiated and papillary carcinomas, similar patterns only 
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appeared in microcarcinomas. 
 
Among previous studies examining the association between thyroid cancer risk and smoking, 
Four15, 18, 20, 21showed an inverse association for current versus never smokers and thyroid cancer 
risk. Consistent with these studies15, 18, 20, 21, our results also show an inverse association of being 
a current smoker.  
 
It remains unclear why the relation between smoking status and thyroid cancer risk only exists 
for current smokers regardless of thyroid cancer subtypes, tumor size and gender. Previous 
studies have demonstrates some potential underlying mechanisms26. In comparison with never or 
former smokers, the level of thyroid stimulating hormone (TSH), serum thyroid autoantibodies 
are lower in current smokers26. High TSH and serum thyroid autoantibody level have been 
suggested to be related with increased risk of thyroid cancer16. Therefore, any agent that could 
lower TSH and thyroid autoantibodies level may play a protective role. Another potential 
mechanism is by altering sex steroid hormone levels27, 28. Incidence of thyroid cancer is higher in 
women than men1, which provides support for the role of estrogens in thyroid carcinogenesis29. 
Thus, by functioning as an anti-estrogen, current smoking status could possibly influence the 
thyroid cancer risk and similar inverse association has been already observed in endometrial 
cancer30. 
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Another possible biologic support for our finding of association between thyroid cancer risk and 
smoking predictor variable may be due to gene-environmental interaction. Studies have shown 
that Cytochrome P4501A1 (CYP1A1) gene variants are associated with thyroid cancer risk31, 32. 
CYP1A1 gene encodes for the enzyme aryl hydro-carbon hydroxylase (AHH), which plays a 
very critical part in transforming polycyclic aromatic hydrocarbons (PAH) that found in cigarette 
smoke, into carcinogens33. Variable ability in different individual to biotransform potentially 
toxic substances has been associated with greater or lesser susceptibility to toxicity and 
subsequent thyroid cancer risk34. It is possible that distinct patterns of CYP1A1 genotypes 
provide a partial explanation for discrepancies in the association between smoking status and 
susceptibility to thyroid cancer. Further study with regard to the interaction of smoking and 
CYP1A1 polymorphism and its influence on thyroid carcinomas is needed. 
 
Our study suggests that longer smoking duration was associated with decreased thyroid cancer 
risk, which is consistent with two previous case-control studies by Krelger et al. 16 and Galanti et 
al.6. Besides, the results also showed an inverse dose-response effect associated with smoking 
duration, which is also consistent with previous epidemiology studies. In a population-based case 
control study conducted in Canada by Krelger et al.16, smoking duration was associated with 
decreased risk of thyroid cancer, in both women and men, and the inverse dose-response was 
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highly statistically significant. Women’s Health Initiative (WHI) study20 also showed a 
marginally significant inverse linear association between papillary carcinoma and smoking 
duration. There is no reduced risk among smokers who initiated smoking younger than 20 years 
old or smokers who had quit smoking less than 13 years prior to enrollment in our study. Similar 
findings were also observed among previous studies with regard to age started smoking 6, 16, 20 
and years since stopped smoking16, 20. 
 
A significant decreased risk only among lowest intensity category (less than 10 cigarettes per day) 
is demonstrated in our results and there is no inverse trends compared to the results reported in 
the Canadian study16. It may be due to the smaller sample size in our study and potential under 
reporting of cigarette smoking history among cases. Although lowest intensity category and 
longest duration are associated with reduced risk of thyroid cancer, there is no significant 
association in any pack-years category, which is defined as pack per day times years of smoking. 
Among five studies that examined the effect of pack years12, 15, 16, 20, 22, the Canadian case-control 
study16 and prospective WHI cohort study20 found negative association between pack-years and 
thyroid cancer risk, which might still due to its large sample size. The remaining three studies 
found no association. 
 
When we stratified by tumor size in both well-differentiated carcinoma and papillary carcinoma, 
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similar results seen in Table 2 are only observed among microcarcinomas, but not in 
macrocarcinomas. And the point estimate is smaller in microcarcinomas compared to all cases 
combined. It is still unequivocal why microcarcinomas are more susceptible to smoking 
exposure. It is very likely that smoking-associated-thyroid microcarcinomas is related to a new 
disease with a different etiology.  An observational study of papillary microcarcinomas from 
Japan demonstrated that 6.4% and 15.9% of patients whose papillary microcarcinomas showed 
enlargement by 3 mm or more on 5-year and 10-year follow-up, respectively, and enlargement 
process was not associated with patient background or clinical features 35.  
 
In this study, trained interviewers used in-person, standardized, and structured interviews to 
minimize the information bias resulting from exposure misclassification. Subjects were asked 
standard, detailed questions with respect to their smoking history. Therefore the smoking status, 
instead of yes or no, was measured in several different aspects including age began smoking, 
intensity and duration of smoking, lifetime cumulative exposure to smoke and age since quitting 
smoking. Thus we could investigate which part of cigarette smoking, if any, has an impact on the 
risk of thyroid cancer. Another strength is that the participation rate in both cases and controls 
are high. Besides, carefully reviewed pathologic reports allowed the stratified analysis based on 
the pathological information. 
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Some limitations should be taken into consideration when interpreting the results. One of our 
drawbacks is that the smoking predictors were based on self-reporting. Therefore, potential recall 
bias cannot be ruled out.  Bias could result from social desirability, which may affect the 
accuracy of smoking status36. In addition, there is no internal exposure measurement of smoking. 
Study has showed that the saliva cotinine levels of smokers varies, even though they smoked 
same number of cigarettes everyday37. Other factors such as the depth and duration of inhalation, 
number of puffs per cigarette and tapering of ventilation holes, etc. could also have an impact on 
the precise smoking exposure measurement38. Finally, due to the sample size limitation, we 
could not investigate the association between smoking status and rare histologic subtypes such as 
follicular, medullary and anaplastic thyroid cancer. 
 
6. Conclusion 
In summary, this population-based case-control study supported that hypothesis that cigarette 
smoking is associated with a reduced risk of thyroid cancer, and the risk may varied by 
histologic subtype. The novel finding that a reduced risk was only associated with thyroid 
microcarcinomas warrant further investigation. 
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Appendix 
A.1  List of abbreviations 
z AHH: aryl hydro-carbon hydroxylase  
z BMI: Body mass index 
z CI: Confidence interval 
z CYP1A1: Cytochrome P450 1A1 
z IARC: The International Agency for Research on Cancer 
z ICD: International Classification of Diseases 
z OR: Odds ratio 
z PAH: Polycyclic aromatic hydrocarbon 
z RCA: Rapid Case Ascertainment Shared Resource 
z SD: Standard deviation 
z TSH: thyroid stimulating hormone 
z US-SG: US Surgeon General 
z WHI: Women’s Health Initiative  
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A.2  List of previous studies on smoking and thyroid cancer 
Author 
(by year) 
Setting Design Sample 
Size/Cases 
Exposure 
assessment 
Exposure 
measurement 
Result 
OR (95% CI) 
Conclusion 
Zivaljevic 
(2013)11 
Belgrade,  
Serbia 
2005-2010 
Case-control 
study 
408/204 
All males 
Self-report Smoking 
status, 
duration,  
intensity 
Smoking status: 
Ever smoker, among males 
0.36 (0.19-0.69) 
Significantly 
negative association 
Kabat 
(2010)20 
WHI study, 
USA 
1991-2010 
Prospective 
cohort study 
159,340 
(331 
cases) 
Self-report Smoking 
status, age at 
initiation, 
duration, 
intensity, 
pack-years,  
All cancer combined: 
 Current: 0.54 (0.29-1.00) 
 Intensity: 
0-4: 1.13 (0.79-1.60) 
5-14: 1.22 (0.91-1.65) 
Age at initiation:  
<20: 1.13 (0.88-1.45) 
>=20: 1.00 (0.75-1.33) 
Duration: 
>=30: 0.79 (0.55-1.22) 
P for linear trend: 0.12 
 
Among papillary carcinoma 
 Current: 0.34 (0.15-0.78) 
 Intensity: 
0-4: 1.20 (0.82-1.74) 
5-14: 1.26 (0.91-1.75) 
Duration: 
>=30: 0.68 (0.44-1.04) 
P for linear trend: 0.06 
 Pack-years 
>=40: 0.44 (0.21-0.89) 
P for linear trend: 0.08 
 
 
Negative association 
between papillary 
carcinoma risk and 
current smoking 
status and pack-years 
greater or equal to 
40. 
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A.2  List of previous studies on smoking and thyroid cancer (continued) 
Author 
(by year) 
Setting Design Sample 
Size/cases 
Exposure 
assessment 
Exposure 
measurement 
Result 
OR (95% CI) 
Conclusion 
Melnhold 
(2010)21 
US 
1983-2006 
Prospective 
cohort study 
90,713  
(282 cases) 
Self-report Smoking status, 
intensity 
Among females: (HR) 
 Current smoker: 
0.54 (0.35-0.82) 
 Intensity: 
  Current>=20: 0.38 (0.18-
0.82) 
Significantly negative 
association among 
current smoker and 
intensity greater or 
equal to 20 cigarettes 
per day. 
Gulgnard 
(2007) 12 
New 
Caledonia, 
France 
1993-1999 
Case-control 
study 
744/232 Self-report Smoking status, 
pack-years 
Smoking status: 
 Among females: 
  Current smoker 
0.96 (0.63-1.45) 
 Pack years: 
0-10: 1.24 (0.79-1.95) 
10-20: 0.48 (0.21-1.07) 
20-30: 1.09 (0.53- 2.77) 
>30: 0.87 (0.37-2.02) 
  P for trend: 0.39 
No association 
Navarro 
Silvers 
(2005)22 
Canada 
1982-2000 
Prospective 
cohort study 
89,716 
(169 cases) 
Self-report Smoking status, age 
at initiation, 
duration, intensity, 
pack-years 
Among all cancer types 
combined: (HR) 
Current smoker: 1.01 
(0.67-1.53) 
Duration: 
>=20: 1.02 (0.70-1.49) 
P for linear trend: 0.77 
Intensity: 
<10: 1.04 (0.63-1.72) 
P for linear trend: 0.91 
No association 
Zivaljevic 
(2004)13 
Belgrade,  
Serbia 
1996-2000 
Case-control 
study 
408/204 Self-report Age at initiation 
 
Initiation age<20, among 
females 
0.66 (0.50-0.90) 
Significantly 
negative association 
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A.2  List of previous studies on smoking and thyroid cancer (continued) (continued) 
Author 
(by 
year) 
Setting Design Sample 
Size/cases 
Exposure 
assessment 
Exposure 
measurement 
Result 
OR (95% CI) 
Conclusion 
Mack 
(2003)24 
Los 
Angeles, 
USA 
1980-1983 
Case-control 
study 
598/302 Self-report Smoking status,  
age at initiation, 
intensity, 
duration 
Among females: 
Current smoker: 
1.1 (0.7-1.7) 
Former smoker: 
0.9 (0.6-1.4) 
No association 
Memon 
(2002)14 
Kuwait 
1998-1999 
Case-control 
study 
626/313 Self-report Smoking status Ever smoker: 
1.6 (1.0-1.8) 
No association 
Iribarren 
(2001)23 
California, 
USA 
1964-1997 
Retrospective 
cohort study 
204,964 
(196 cases) 
Self-report Smoking status Current smokers: 
RR:1.01 (0.71-1.42) 
No association 
Rossing 
(2000)15 
Washington, 
USA 
1988-1994 
Case-control 
study 
1,042/468 Self-report Smoking status, 
age  
at initiation, 
duration, 
intensity 
pack-years, 
years since  
quitting 
Among female papillary 
carcinoma 
Current smoker: 
0.5 (0.4-0.7) 
Age at initiation: 
 8-14: 0.5 (0.3-0.9) 
 15-17:0.6 (0.3-1.0) 
 18-19: 0.5 (0.3-1.0) 
20-36: 0.5 (0.2-1.0) 
Intensity: 
<10: 0.5 (0.3-1.2) 
>10: 0.5 (0.3-0.9) 
Pack-years: 
<5: 0.5 (0.3-1.0) 
5-10: 0.6 (0.3-1.1) 
10-20: 0.5 (0.2-0.9) 
>20: 0.6 (0.3-1.0) 
Significantly negative 
association in current 
smoker, age at initiation 8-
14, intensity greater than 10 
cigarettes per day and 10-20 
pack-years. 
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A.2  List of previous studies on smoking and thyroid cancer (continued)) 
Author 
(by 
year) 
Setting Design Sample 
size 
Exposure 
assessment 
Exposure 
measurement 
Result 
OR (95% CI) 
Conclusion 
Krelger 
(2000)16 
Canada 
1986-1988 
Case-
control 
study 
3883/1224 
for smoking 
status; 
1316/264 
for other 
smoking 
predictors 
Self-report Smoking status,  
age at initiation, 
intensity, 
duration, pack-
years, 
Years since 
quitting 
Among females: 
Ever smoker: 
0.71 (0.60-0.83) 
Age at initiation: 
<15: 0.75 (0.51-1.08) 
15-19: 0.69 (0.57-0.84) 
20-24: 0.63 (0.46-0.85) 
>24: 0.83 (0.56-01.21) 
P for linear trend: ns 
Duration: 
<10: 1.05 (0.82-1.34) 
11-20: 0.68 (0.52-0.89) 
21-30: 0.48 (0.35-0.66) 
>30: 0.55 (0.40-0.76) 
P for linear trend:0.0003 
Intensity: 
<10: 0.91 (0.72-1.14) 
11-19: 0.86 (0.65-1.14) 
20-25: 0.54 (0.42-0.69) 
>25 0.46 (0.30-0.70) 
P for linear trend:0.0002 
Pack-years: 
<=4: 1.02 (0.79-1.31) 
4.1-10: 0.79 (0.60-1.05) 
10.1-25: 0.58 (0.45-0.75) 
Significantly negative  
associations 
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>25: 0.46 (0.33-0.64) 
P for linear trend:0.0001 
Years since quitting: 
<3: 0.67 (0.55-0.81) 
3-8: 0.97 (0.70-1.35) 
9-15: 0.59 (0.41-0.85) 
>15: 0.73 (0.51-1.06) 
P for linear trend: ns 
Galanti 
(1996)6 
Norway and  
Sweden 
1993-1994 
Case-
control 
study 
532/191 Self-report Intensity, 
duration, 
age at initiation 
Among females: 
Intensity: 
1-7: 0.69 (0.47-1.01) 
8-10: 0.94 (0.54-1.62) 
11-15: 0.64 (0.38-1.06) 
>=16: 0.71 (0.33-1.51) 
Duration: 
1-10: 0.85 (0.50-1.46) 
11-20: 0.55 (0.31-0.97) 
>=21: 0.71 (0.41-1.23) 
Age at initiation: 
<15: 0.38 (0.18-0.80) 
15-19: 0.74 (0.47-1.16) 
Significantly negative 
association among 11-20 years 
of duration, and age at 
initiation less than 15 years. 
Sokic 
(1994)17 
Belgrad, 
Serbia 
 
Case-
control 
study 
200/100 Self-report Smoking status Ever smoker: 
7.12 (1.53-32.99) 
No association 
Hallquist 
(1993)18 
Sweden 
 
Case-
control  
study 
540/180 Self-report Smoking status Among females: 
Former smoker: 
0.5 (0.2-0.96) 
Current smoker: 
0.6 (0.3-0.96) 
Significantly negative 
association among former and 
current smokers 
Ron 
(1987)19 
Connecticut, 
USA 
 
Case-
control  
study 
444/159 Self-report Smoking status No OR and 95% CI  
was provided 
No association 
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Table 1. Selected characteristics of thyroid cancer among cases and controls  
    Cases (n=462)   Controls (n=498)  p-value  
    # %   # % 
Age (years)     
 
    <0.01 
 
Mean (SD) 51.2 (12.3) 
 
54.2 (13.1) 
 
 
<40 64 12.9 
 
86 18.6 
 
 
40- 123 24.7 
 
115 24.9 
 
 
50- 139 27.9 
 
149 32.3 
 
 
60- 100 20.1 
 
81 17.5 
 
 
≥ 70 72 14.5 
 
31 6.7 
 Gender 
     
0.0003 
 
Femal 375 81.2 
 
344 69.1 
 
 
Male 87 18.8 
 
154 30.9 
 Race 
      
0.33 
 
White 415 89.8 
 
450 90.5 
 
 
Black 18 3.9 
 
25 5.0 
 
 
Other 29 6.3 
 
23 4.5 
 BMI (kg m-2) 
     
<0.01 
 
<25 145 31.4 
 
203 40.8 
 
 
25-29.99 146 31.6 
 
168 33.7 
 
 
≥30 166 35.9 
 
118 23.7 
 Education 
     
<0.01 
 
High school or less 129 27.9 
 
88 17.7 
 
 
Some college 31 6.7 
 
25 5.0 
 
 
College graduate or more 285 61.7 
 
366 73.5 
 
 
Others 13 2.8 
 
13 2.6 
 Family history of any cancer 
   
0.75 
 
None  143 31.0 
 
159 31.9 
 
 
Any cancer 319 69.0 
 
339 68.1 
 Prior benign thyroid disease§ 
   
<0.01 
 
Yes 259 56.0  20 4.0  
 
No 203 44.0  478 96.0  
Previous radiation exposure‡    0.68 
 
Yes 456 98.7  488 98.0  
 
No 1 0.2  2 0.4  
Alcohol consumption† 
    
<0.01 
 
Never 270 58.4 
 
226 45.4 
   Ever 188 40.7   267 53.6   
 
§ Benign thyroid diseases included hyperthyroidism, hypothyroidism, goiter, thyroid 
nodules, and thyroid adenoma. 
  29 
‡ Previous radiation exposure included previous diagnosis and therapeutic radiation 
exposure 
†Ever alcohol consumption was defined as ever had more than 12 drinks of alcoholic 
beverages such as beer, wine, or liquor.  1drink beer=1 can or bottle; 1 drink wine =14 oz 
glass; 1 drink liquor= 1 shot.           
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Table 2.  Risk of thyroid cancer associated with cigarette smoking for all thyroid cancer 
cases combined 
    Cases (n=458) § Controls (n=493) § OR* 95% CI 
    # # 
Smoking     
 
Never 317 321 1.00 - 
 
Ever 141 172 0.82 (0.57, 1.17) 
 
Current 42 52 0.56 (0.31, 1.01) 
 
Former 98 118 0.97 (0.65, 1.46) 
Age at initiation (years)    
 
< 20 106 130 0.74 (0.50, 1.10) 
 
≥ 20 35 42 1.17 (0.62, 2.21) 
 
P for linear trend  0.40  
Intensity (# cig/day)    
 
<10 39 75 0.52 (0.30, 0.90) 
 
10 -< 20 60 63 0.87 (0.52, 1.46) 
 
≥ 20 39 33 1.42 (0.76, 2.66) 
 
P for linear trend  0.58  
Duration (years)    
 
< 10 36 50 1.10 (0.63, 1.92) 
 
10 -< 29 70 62 1.00 (0.61, 1.64) 
 
>- 29 34 58 0.42 (0.23, 0.81) 
 
P for linear trend  0.01  
Pack-years     
 
<5 36 53 1.02 (0.58, 1.77) 
 
5 -<  24 48 61 0.58 (0.33, 1.01) 
 
≥ 24 53 55 0.93 (0.53, 1.62) 
 
P for linear trend  0.85  
Years since quitting 
   
 
<13 31 39 0.79 (0.41, 1.52) 
 
13 -< 28 39 40 0.91 (0.49, 1.70) 
 
≥ 28 28 39 1.29 (0.68, 2.46) 
  P for linear trend   0.45   
 
*Adjusted for age, gender, race, family history of any cancer, education, BMI, prior 
benign thyroid disease, and previous alcohol consumption. 
§ Numbers may not sum to total due to missing data. 
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Table 3. Risk of thyroid cancer associated with cigarette smoking for thyroid cancer 
histological subtypes 
Smoking Controls (n=498)§ 
Papillary 
 (n= 392)   
Well differentiated 
(n=448 ) 
Cases § OR*95% CI   Cases § OR*95% CI 
Smoking 
      
 
Never 326 273 1.00  
 
313 1.00 
 
Ever 172 119 0.85 (0.58, 1.24) 
 
135 0.80 (0.56, 1.16) 
 
Current 52 35 0.59 (0.32, 1.10) 
 
39 0.51 (0.28, 0.94) 
 
Former 118 83 0.99 (0.65, 1.52) 
 
95 0.97 (0.64, 1.47) 
Age at initiation 
(years) 
     
 
< 20 130 89 0.75 (0.49, 1.13) 
 
102 0.74 (0.49, 1.10) 
 
≥ 20 42 30 1.31 (0.67, 2.58) 
 
33 1.10 (0.57, 2.14) 
 
P for linear trend 
 
0.32  
  
0.41 
Intensity (# cig/day) 
     
 
<10 75 36 0.62 (0.36, 1.08) 
 
38 0.53 (0.31, 0.93) 
 
10 -< 20 63 49 0.85 (0.49, 1.48) 
 
58 0.85 (0.50, 1.44) 
 
≥ 20 33 31 1.33 (0.67, 2.62) 
 
36 1.32 (0.69, 2.51) 
 
P for linear trend 
 
0.80  
  
0.84 
Duration 
(years)  
     
 
< 10 50 32 1.24 (0.69, 2.20) 
 
36 1.15 (0.65, 2.01) 
 
10 -< 29 62 60 1.01 (0.60, 1.71) 
 
66 0.96 (0.58, 1.59) 
 
≥ 29 58 26 0.38 (0.19, 0.77) 
 
32 0.40 (0.21, 0.76) 
 
P for linear trend 
 
0.01  
  
0.01 
Pack-years       
 
0 - 5 53 32 1.14 (0.65, 2.02) 
 
35 1.06 (0.61, 1.86) 
 
5 - 24 61 46 0.69 (0.39, 1.20) 
 
48 0.60 (0.34, 1.04) 
 
≥ 24 55 37 0.73 (0.39, 1.37) 
 
48 0.81 (0.45, 1.45) 
 
P for linear trend 
 
0.73  
  
0.89 
Years since quitting 
     
 
<13 39 28 0.81 (0.41, 1.61) 
 
31 0.82 (0.43, 1.58) 
 
13 -< 28 40 31 0.85 (0.44, 1.67) 
 
38 0.88 (0.47, 1.67) 
 
≥ 28 39 24 1.46 (0.74, 2.87) 
 
26 1.32 (0.68, 2.55) 
  P for linear trend   0.37     0.46  
*Adjusted for age, gender, race, family history of any cancer, education, BMI, history of 
goiter, history of thyroid nodules, history of radiation exposure and previous alcohol use. 
§ Numbers may not sum to total due to missing data. 
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         Table 4. Risk of thyroid cancer associated with cigarette smoking for thyroid cancer by tumor size 
Smoking Controls (n=498)§ 
Well-differentiated carcinoma   Papillary carcinoma 
≤ 1cm (n=214) 
 
> 1cm (n=229)   ≤ 1cm (n=190) 
 
> 1cm (n=199) 
Cases§ OR*95% CI   Cases§ OR*95% CI   Cases§ OR*95% CI   Cases§ OR*95% CI 
Smoking 
 
     
 
     
 
Never 321 150 1.00  160 1.00   
133 1.00  138 1.00 
 
Ever 172 64 0.65 (0.41, 1.04)  69 0.79 (0.49, 1.27)  
57 0.71 (0.44, 1.16)  61 0.81 (0.50, 1.33) 
 
Current 52 15 0.30 (0.13, 0.70)  24 0.73 (0.35, 1.40) 
 
14 0.36 (0.15, 0.84)  21 0.78 (0.37, 1.66) 
 
Former 118 49 0.90 (0.53, 1.50)  44 0.81 (0.47, 1.40) 
 
43 0.96 (0.56, 1.65)  39 0.81 (0.46, 1.43) 
Age at initiation (years) 
          
 
< 20 130 50 0.57 (0.34, 0.97) 
 
57 0.72 (0.43, 1.21) 
 
41 0.62 (0.36, 1.07) 
 
50 0.71 (0.42, 1.22) 
 
≥ 20 42 14 1.01 (0.44, 2.31) 
 
12 1.12 (0.48, 2.64) 
 
16 1.15 (0.49, 2.72) 
 
11 1.31 (0.55, 3.11) 
 
P for linear trend 
 
0.43  
  
0.51 
  
0.54 
  
0.32 
Intensity (# cig/day) 
           
 
<10 75 12 0.33 (0.15, 0.74) 
 
26 0.67 (0.35, 1.30) 
 
12 0.39 (0.17, 0.88) 
 
24 0.75 (0.39, 1.47) 
 
10 -< 20 63 36 0.84 (0.45, 1.57) 
 
21 0.55 (0.26, 1.15) 
 
31 0.91 (0.47, 1.76) 
 
17 0.47 (0.21, 1.04) 
 
≥ 20 33 14 0.92 (0.38, 2.20) 
 
21 1.72 (0.77, 3.77) 
 
12 
0.94 (0037, 
2.39) 
 
19 1.90 (0.85, 4.22) 
 
P for linear trend 
 
0.86  
  
0.88 
  
0.97 
  
0.80 
Duration (years) 
           
 
< 10 50 20 1.03 (0.51, 2.08) 
 
15 1.06 (0.50, 2.22) 
 
18 1.17 (0.57, 2.43) 
 
13 1.05 (0.48, 2.28) 
 
10 -< 29 62 32 0.90 (0.48, 1.69) 
 
34 0.86 (0.45, 1.67) 
 
27 0.94 (0.48, 1.82) 
 
33 0.96 (0.50, 1.86) 
 
≥ 29 58 12 0.18 (0.07, 0.47) 
 
19 0.50 (0.23, 1.11) 
 
12 0.22 (0.09, 0.58) 
 
14 0.45 (0.19, 1.07) 
 
P for linear trend 
 
<0.01 
  
0.06 
  
<0.01 
  
0.07 
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*Adjusted for age, gender, race, family history of any cancer, education, BMI, prior benign thyroid disease, and previous alcohol consumption. 
§ Numbers may not sum to total due to missing data. 
Pack-years 
           
 
0 - 5 53 13 0.75 (0.35, 1.60) 
 
21 1.35 (0.68, 2.69) 
 
12 0.84 (0.38, 1.85) 
 
19 1.36 (0.67, 2.75) 
 
5 - 24 61 27 0.56 (0.28, 1.10) 
 
21 0.38 (0.18, 0.83) 
 
26 0.67 (0.34, 1.32) 
 
20 0.43 (0.19, 0.93) 
 
≥ 24 55 22 0.66 (0.31, 1.42) 
 
25 0.89 (0.42, 1.86) 
 
17 0.61 (0.27, 1.39) 
 
20 0.87 (0.40, 1.89) 
 
P for linear trend 
 
0.97  
  
0.96 
  
0.92  
  
0.93 
Years since quitting 
           
 
<13 39 15 0.64 (0.27, 1.52)  15 0.70 (0.29, 1.70) 
 
14 0.72 (0.30, 1.74) 
 
14 0.66 (0.26, 1.64) 
 
13 -< 28 40 20 0.86 (0.39, 1.91)  18 0.70 (0.31, 1.60)  
16 0.78 (0.33, 1.84) 
 
15 0.76 (0.32, 1.78) 
 
≥ 28 39 14 1.32 (0.59, 2.97)  11 1.16 (0.48, 2.82) 
 
13 1.61 (0.71, 3.69) 
 
10 1.16 (0.46, 2.95) 
  P for linear trend   0.45     0.96     0.25     0.87 
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Table 5. Risk of thyroid cancer associated with cigarette smoking for thyroid cancer 
among follicular carcinoma 
Smoking Controls (n=498) § 
Follicular (n=56 ) 
Cases§ OR*95% CI 
Smoking 
   
 
Never 326 40 1.00 
 
Ever 172 16 0.38 (0.16, 0.90) 
 
Current 52 4 0.19 (0.05, 0.81) 
 
Former 118 12 0.52 (0.20, 1.34) 
Age at initiation (years) 
  
 
< 20 135 13 0.39 (0.16, 0.99) 
 
≥ 20 37 3 0.34 (0.07, 1.76) 
 
P for linear trend 
 
0.98 
Intensity (# 
cig/day) 
   
 
<10 75 2 0.07 (0.01, 0.47) 
 
10 -< 20 63 9 0.44 (0.15, 1.32) 
 
≥ 20 33 5 1.14 (0.29, 4.43) 
 
P for linear trend 
 
0.69 
Duration (years)    
 
< 10 50 4 0.67 (0.18, 2.50) 
 
10 -< 29 62 6 0.36 (0.10, 1.28) 
 
≥ 29 58 6 0.27 (0.08, 0.97) 
 
P for linear trend 
 
0.03 
Pack-years    
 
0 - 5 53 3 0.64 (0.14, 3.04) 
 
5 - 24 61 2 0.04 (0.01, 0.23) 
 
≥ 24 55 11 1.10 (0.37, 3.29) 
 
P for linear trend 
 
0.52 
Years since 
quitting 
   
 
<13 39 3 0.43 (0.09, 2.19) 
 
13 -< 28 40 7 0.60 (0.16, 2.17) 
 
≥ 28 39 2 0.52 (0.09, 2.89) 
  P for linear trend 
 
0.47 
 
*Adjusted for age, gender, race, family history of any cancer, education, BMI, prior 
benign thyroid disease, and previous alcohol consumption. 
§ Numbers may not sum to total due to missing data. 
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Table 6.  Risk of thyroid cancer associated with cigarette smoking among females 
    Controls (n=344) § Cases (n=375) §  OR*95% CI 
Smoking 
 
  
 
Never 227 264 1.00 
 
Ever 117 111 0.76 (0.50, 1.15) 
 
Current 39 37 0.52 (0.27, 1.00) 
 
Former 76 73 0.93 (0.58, 1.49) 
Age at initiation 
(years)    
 
< 20 91 89 0.67 (0.43, 1.06) 
 
≥ 20 26 22 1.14 (0.55, 2.35) 
 
P for linear 
trend   0.37 
Intensity (# cig/day)    
 
<10 60 35 0.50 (0.27, 0.91) 
 
10 -< 20 38 50 0.89 (0.49, 1.62) 
 
≥ 20 19 24 1.13 (0.52, 2.45) 
 
P for linear 
trend   0.92 
Duration (years)    
 
< 10 33 30 1.08 (0.57, 2.03) 
 
10 -< 29 45 52 0.87 (0.49, 1.55) 
 
≥ 29 37 28 0.42 (0.20, 0.86) 
 
P for linear 
trend   0.01 
Pack-years    
 
0 - 5 37 31 0.96 (0.51, 1.79) 
 
5 -< 24 46 40 0.53 (0.29, 0.99) 
 
≥ 24 30 37 0.87 (0.44, 1.71) 
 
P for linear 
trend 
  
0.72 
Years since quitting 
   
 
<13 23 22 0.79 (0.36, 1.73) 
 
13 -< 28 29 29 0.77 (0.37, 1.60) 
 
≥ 28 24 22 1.32 (0.63, 2.78) 
  
P for linear 
trend     0.44 
 
*Adjusted for age, race, family history of any cancer, education, BMI, prior benign 
thyroid disease, and previous alcohol consumption. 
§ Numbers may not sum to total due to missing data. 
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Table 7. Risk of thyroid cancer associated with cigarette smoking among males 
    Controls (n=154) § Cases (n=87) § OR*95% CI 
Smoking 
   
 
Never 99 57 1.00 
 
Ever 55 30 1.07 (0.48, 2.37) 
 
Current 13 5 0.81 (0.18, 3.60) 
 
Former 42 25 1.14 (0.49, 2.64) 
Age at initiation 
(years)    
 
< 20 44 24 1.05 (0.43, 2.54) 
 
≥ 20 11 6 1.14 (0.28, 4.62) 
 
P for linear trend   0.43 
Intensity (# cig/day)    
 
<10 15 4 0.47 (0.10. 2.27) 
 
10 -< 20 25 10 0.85 (0.27, 2.71) 
 
≥ 20 14 15 2.39 (0.74, 7.66) 
 
P for linear trend   0.34 
Duration (years)    
 
< 10 17 6 1.50 (0.42, 5.42) 
 
10 -< 29 17 18 1.51 (0.52, 4.39) 
 
≥ 29 21 6 0.44 (0.11, 1.78) 
 
P for linear trend   0.43 
Pack-years    
 
0 - 5 14 5 1.35 (0.36, 5.13) 
 
5 -< 24 15 8 0.98 (0.27, 3.64) 
 
≥ 24 25 16 0.99 (0.34, 2.83) 
 
P for linear trend 
  
0.95 
Years since quitting 
   
 
<13 16 9 0.89 (0.25, 3.13) 
 
13 -< 28 11 10 1.46 (0.42, 5.05) 
 
≥ 28 15 6 1.15 (0.27, 4.93) 
  P for linear trend     0.85 
 
*Adjusted for age, race, family history of any cancer, education, BMI, prior benign 
thyroid disease, and previous alcohol consumption. 
               § Numbers may not sum to total due to missing data. 
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Table 8. Risk of thyroid cancer associated with cigarette smoking for thyroid cancer 
tumor size among all cancer types 
Smoking Controls (n=498) § ≤ 1cm (n=217)   > 1cm (n=240) 
Cases § OR*95% CI   Cases § OR*95% CI 
Smoking       
 
Never 326 153 1.00  165 1.00  
 
Ever 172 64 0.64 (0.40, 1.02)  75 0.84 (0.53, 1.32) 
 
Current 52 15 0.30 (0.13, 0.69)  27 0.82 (0.41, 1.66) 
 
Former 118 49 0.88 (0.52, 1.47)  47 0.84 (0.49, 1.42) 
Age at initiation (years) 
     
 
< 20 135 50 0.56 (0.34, 0.95) 
 
61 0.74 (0.45, 1.22) 
 
≥ 20 37 14 1.00 (0.44, 2.27) 
 
14 1.30 (0.59, 2.89) 
 
P for linear trend 
 
0.43  
  
0.48 
Intensity (# cig/day) 
     
 
<10 75 12 0.32 (0.14, 0.73) 
 
27 0.65 (0.34, 1.24) 
 
10 -< 20 63 36 0.82 (0.44, 1.54) 
 
23 0.62 (0.31, 1.27) 
 
≥ 20 33 14 0.90 (0.38, 2.16) 
 
24 1.88 (0.90, 3.94) 
 
P for linear trend 
 
0.82  
  
0.48 
Duration (years) 
     
 
< 10 50 20 1.01 (0.50, 2.03) 
 
15 1.00 (0.48, 2.09) 
 
10 -< 29 62 32 0.89 (0.47, 1.67) 
 
38 0.97 (0.52, 1.81) 
 
>- 29 58 12 0.18 (0.07, 0.46) 
 
21 0.56 (0.26, 1.20) 
 
P for linear trend 
 
<0.01 
  
0.11 
Pack-years       
 
0 - 5 53 13 0.73 (0.34, 1.56) 
 
22 1.27 (0.65, 2.51) 
 
5 - 24 61 27 0.55 (0.28, 1.09) 
 
21 0.37 (0.17, 0.81) 
 
≥ 24 55 22 0.65 (0.30, 1.38) 
 
30 1.13 (0.57, 2.24) 
 
P for linear trend 
 
0.97  
  
0.76 
Years since quitting 
     
 
<13 39 15 0.62 (0.26, 1.48) 
 
15 0.67 (0.28, 1.60) 
 
13 -< 28 40 20 0.84 (0.38, 1.86) 
 
19 0.76 (0.34, 1.70) 
 
≥ 28 39 14 1.29 (0.58, 2.89) 
 
13 1.19 (0.51, 2.76) 
  P for linear trend   0.50     0.90 
 
*Adjusted for age, gender, race, family history of any cancer, education, BMI, prior 
benign thyroid disease, and previous alcohol consumption. 
§ Numbers may not sum to total due to missing data.   
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*Adjusted for age, race, family history of any cancer, education, BMI, prior benign 
thyroid disease, and previous alcohol consumption. 
               § Numbers may not sum to total due to missing data. 
  
Table 9. Sensitivity analysis of among papillary carcinoma 
 
    
Smoking 
Papillary carcinoma 
≤ 1cm (n=190) 
 
> 1cm (n=199) 
Controls a Cases a OR*95% CI   
Controls 
a Cases a OR*95% CI 
Smoking 
 
  
  
  
 
Never 88 131 1.00  120 136 1.00 
 
Ever 52 57 0.81 (0.44, 1.51)  53 61 1.24 (0.68, 2.27) 
 
Current 15 14 0.38 (0.12, 1.20)  16 21 1.17 (0.46, 2.98) 
 
Former 37 43 1.03 (0.52, 2.02)  37 39 1.23 (0.62, 2.45) 
Age at initiation (years)       
 
< 20 47 45 0.64 (0.33, 1.24)  44 50 1.03 (0.53, 1.99) 
 
≥ 20 5 12 2.53 (0.71, 8.99)  9 11 2.53 (0.81, 7.86) 
 
P for linear trend  0.02    0.03 
Intensity (# cig/day)       
 
<10 26 12 0.35 (0.13, 0.91)  27 24 0.84 (0.38, 1.85) 
 
10 -< 20 15 31 1.46 (0.62, 3.44)  18 17 1.18 (0.46, 3.08) 
 
≥ 20 11 12 0.97 (0.27, 3.42)  8 19 3.33 (1.11, 10.06) 
 
P for linear trend  0.73    0.12 
Duration (years)       
 
< 10 12 18 1.68 (0.66, 4.28)  15 13 1.48 (0.56, 3.91) 
 
10 -< 29 28 27 0.68 (0.31, 1.48)  27 33 1.17 (0.54, 2.50) 
 
≥ 29 12 12 0.23 (0.05, 1.04)  11 14 1.02 (0.34, 3.08) 
 
P for linear trend  0.02    0.82 
Pack-years        
 
0 - 5 14 12 1.08 (0.41, 2.82)  13 19 2.21 (0.89, 5.50) 
 
5 - 24 24 26 0.70 (0.31, 1.56)  26 20 0.67 (0.28, 1.58) 
 
≥ 24 14 17 0.58 (0.17, 2.00)  14 20 1.37 (0.52, 3.65) 
 
P for linear trend  0.70    0.47 
Years since quitting       
 
<13 12 14 1.08 (0.37, 3.15)  10 14 1.83 (0.60, 5.55) 
 
13 -< 28 11 16 1.05 (0.35, 3.16)  13 15 1.02 (0.37, 2.80) 
 
≥ 28 14 13 0.96 (0.34, 2.73)  14 10 1.07 (0.35, 3.23) 
  P for linear trend   0.63       0.96 
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*Adjusted for age, race, family history of any cancer, education, BMI, prior benign 
thyroid disease, and previous alcohol consumption. 
§ Numbers may not sum to total due to missing data.  
Smoking 
Well-differentiated carcinoma 
≤ 1cm (n=214) 
 
> 1cm (n=229) 
Controls§ Cases§ OR*95% CI 
 
Controls§ Cases§ OR*95% CI 
Smoking 
  
 
  
  
 
Never 103 148 1.00 
 
125 158 1.00  
 
Ever 53 64 0.80 (0.45, 1.44) 
 
56 69 1.21 (0.68, 2.13) 
 
Current 15 15 0.35 (0.11, 1.11) 
 
16 24 1.09 (0.43, 2.76) 
 
Former 39 49 1.01 (0.53, 1.93) 
 
40 44 1.22 (0.65, 2.32) 
Age at initiation (years) 
      
 
< 20 49 50 0.63 (0.33, 1.20) 
 
46 57 1.07 (0.58, 1.98) 
 
≥ 20 5 14 2.37 (0.69, 8.19) 
 
10 12 1.92 (0.66, 5.65) 
 
P for linear trend 
 
0.02  
   
0.15 
Intensity (# cig/day) 
      
 
<10 26 12 0.34 (0.13, 0.86) 
 
31 26 0.72 (0.34, 1.53) 
 
10 -< 20 17 36 1.34 (0.59, 3.03) 
 
18 21 1.40 (0.58, 3.42) 
 
≥ 20 11 14 1.06 (0.32, 3.46) 
 
7 21 3.61 (1.19, 10.93) 
 
P for linear trend 
 
0.72  
   
0.09 
Duration (years) 
      
 
< 10 16 20 1.29 (0.54, 3.08) 
 
18 15 1.44 (0.58, 3.56) 
 
10 -< 29 27 32 0.75 (0.36, 1.57) 
 
25 34 1.15 (0.55, 2.42) 
 
≥ 29 11 12 0.22 (0.05, 1.09) 
 
13 19 0.99 (0.36, 2.71) 
 
P for linear trend 
 
0.05  
   
0.76 
Pack-years 
       
 
0 - 5 16 13 0.98 (0.39, 2.46) 
 
17 21 1.98 (0.85, 4.60) 
 
5 - 24 24 27 0.63 (0.29, 1.40) 
 
26 21 0.60 (0.26, 1.39) 
 
≥ 24 14 22 0.80 (0.26, 2.43) 
 
13 25 1056 (0.61, 4.00) 
 
P for linear trend 
 
0.41  
   
0.33 
Years since quitting 
      
 
<13 12 15 1.06 (0.37, 3.01) 
 
12 15 1.58 (0.57, 4.35) 
 
13 -< 28 12 20 1.26 (0.45, 3.48) 
 
13 18 1.06 (0.40, 2.80) 
 
≥ 28 15 14 0.78 (0.28, 2.17) 
 
15 11 1.12 (0.39, 3.19) 
  P for linear trend   0.83       0.71 
Table 10. Sensitivity analysis among well-differentiated carcinoma 
